Kymera Therapeutics to Participate in Upcoming September Conferences
29 août 2022 07h30 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Announces $150 Million Private Placement Equity Financing
19 août 2022 07h30 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Business Update
09 août 2022 07h00 HE
|
Kymera Therapeutics, Inc.
Initiated dosing in patient cohort (Part C) of IRAK4 degrader KT-474 Phase 1 trial, on track for data by year end Phase 1 patient studies initiated for STAT3 (KT-333) and IRAKIMiD (KT-413)...
Kymera Therapeutics to Report Second Quarter 2022 Results on August 9
27 juil. 2022 07h30 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan
08 juil. 2022 07h30 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., July 08, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Peripheral T-Cell Lymphoma
01 juin 2022 08h42 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Therapeutics to Present Pre-clinical Data at the EULAR 2022 Congress Showing STAT3 Degradation Blocked Th17 Development and Prevented Rheumatoid Arthritis
01 juin 2022 07h00 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Therapeutics Presented Preclinical Data Showcasing Impact of IRAK4 Degrader KT-474 on Immune and Skin Cells at the Society for Investigative Dermatology Annual Meeting
20 mai 2022 07h30 HE
|
Kymera Therapeutics, Inc.
WATERTOWN, Mass., May 20, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...
Kymera Therapeutics to Share Novel Preclinical Findings Reinforcing the Advantage of IRAK4 Degraders over Kinase Inhibitors as well as First STAT3 Degrader Results in a Preclinical Model of Th17 Inflammation
05 mai 2022 08h00 HE
|
Kymera Therapeutics, Inc.
-Data to be shared at the American Association of Immunologists (AAI) Annual Meeting -Results highlight potential for IRAK4 degraders to broadly impact TLR/IL-1R-driven inflammatory and autoimmune...
Kymera Therapeutics Announces First Quarter 2022 Financial Results and Provides a Business Update
03 mai 2022 07h00 HE
|
Kymera Therapeutics, Inc.
IRAK4 degrader KT-474 Phase 1 patient cohort amended to extend dosing from 14 to 28 days, enabling inclusion of exploratory clinical efficacy endpoints and extended safety monitoring Clinical...